綠葉製藥(02186.HK)就LY09004與歐康維視訂立合作及獨家推廣協議
格隆匯 10 月 30日丨綠葉製藥(02186.HK)發佈公告,集團附屬公司山東博安生物技術有限公司與歐康維視生物(01477.HK)的全資附屬公司歐康維視(浙江)醫藥有限公司訂立合作及獨家推廣協議,以共同開發博安生物正在進行III期臨牀試驗的LY09004(EYLEA®(阿柏西普)的生物類似藥)。此外,博安生物授予浙江歐康維視在中國內地獨家推廣及商業化LY09004的權利。
根據協議,博安生物授予歐康維視在中國內地獨家推廣及商業化LY09004的權利,而博安生物繼續持有該產品在協議地區的資產權、註冊準證等推廣和商業化以外的權利,以及除協議地區外的全球權利。浙江歐康維視將在協議簽署後向博安生物支付首付款,並在達成若干開發及監管里程碑後,向博安生物支付開發里程碑付款。於LY09004獲准於地區內銷售後,浙江歐康維視將向博安生物支付若干銷售里程碑付款及按其年度銷售淨額支付特定比例的銷售提成。此外,浙江歐康維視承擔地區內與目標產品III期臨牀試驗相關的所有費用。協議有效期至LY09004產品上市許可批准並完成第一筆發貨之日後10年。
董事會相信,歐康維視生物作為知名眼科公司,具備專業的團隊,將加快推動LY09004的臨牀試驗及商業化,以滿足中國患者迫切的臨牀需求,增強集團在生物製品領域的行業地位。除中國市場外,博安生物還在美國、日本、歐洲等國家或地區開發該等產品。根據公開資料顯示,EYLEA®(阿柏西普眼內注射液)於2019年的全球銷售額為75.42億美元,同比增長12%,可見該等產品在全球市場的需求及增長潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.